Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

Gynecologic oncology - 1 Oct 2009

Vicus Danielle, Rosen Barry, Lubinski Jan, Domchek Susan, Kauff Noah D, Lynch Henry T, Isaacs Claudine, Tung Nadine, Sun Ping, Narod Steven A

Abstract excerpt

OBJECTIVE: BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Genes, BRCA1

Share to Genetic Predisposition to Disease

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 19577280
DOI: 10.1016/j.ygyno.2009.06.012
PMCID: PMC3756313

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.PMID 19577280Read ↗

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.Semantic proximity Read ↗

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.Semantic proximity Read ↗

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.Semantic proximity Read ↗

Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.Semantic proximity Read ↗

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

BRCA1 germline mutations may be associated with reduced ovarian reserve.Semantic proximity Read ↗

Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Failure of BRCA1 dysfunction to alter ovarian cancer survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.